The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 104-111

  Sternberg, Zohara ^a   Leung, Christopher ^a   Sternberg, Daniel ^a   Li, Fan ^b   Karmon, Yuval ^a   Chadha, Kailash ^c   Levy, Elad ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b the State University of New York   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Blood pressure; Dyslipidemia; Homocysteine; Inflammation; Multiple sclerosis; Plasma glucose

Indexed keywords

ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; COLECALCIFEROL; CYANOCOBALAMIN; DIURETIC AGENT; FERRITIN; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IRON; TRIACYLGLYCEROL; URIC ACID; VITAMIN;

ADULT; AGED; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; IRON BINDING CAPACITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84875317729     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010016     Document Type: Review

References (39)

1. Ross, J.L.; Manuszak, M.A.; Wachs, J.E. Identification and management of vascular risk: beyond low density lipoprotein cholesterol. AAOHN J. Offic. J. Am. Assoc. Occup. Health Nurses, 2003, 51, 521-531, quiz 532-523.
2. Kolovou, G.D.; Anagnostopoulou, K.K.; Salpea, K.D.; Mikhailidis, D.P. The prevalence of metabolic syndrome in various populations. Am. J. Med. Sci., 2007, 333, 362-371.
3. Madjid, M.; Willerson, J.T. Inflammatory markers in coronary heart disease. Br. Med. Bull., 2011, 100, 23-38.
4. Elkind, M.S.; Rundek, T.; Sciacca, R.R.; Ramas, R.; Chen, H.J.; Boden-Albala, B., Rabbani, L.; Sacco, R.L. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis, 2005, 180, 181-187.
5. Elkind, M.S.; Cheng, J.; Boden-Albala, B.; Rundek, T.; Thomas, J.; Chen, H.; Rabbani, L.E.; Sacco, R.L. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis, Stroke. J. Cereb. Circul., 2002, 33, 31-37.
6. Sedeek, M.; Hebert, R.L.; Kennedy, C.R.; Burns, K.D.; Touyz, R.M. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr. Opin. Nephrol. Hypertens., 2009, 18, 122-127.
7. Schmidt, M.I.; Duncan, B.B. Diabesity: an inflammatory metabolic condition, Clinical chemistry and laboratory medicine. CCLM/FESCC, 2003, 41, 1120-1130.
8. Koch, M.; Mostert, J.; Arutjunyan, A.; Stepanov, M.; Teelken, A.; Heersema, D.; De Keyser, J. Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. Mult. Scler., 2008, 14, 159-165.
9. Rieckmann, P.; Albrecht, M.; Kitze, B.; Weber, T.; Tumani, H.; Broocks, A.; Lüer, W.; Helwig, A.; Poser, S.Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurology, 1995, 37, 82-88.
10. Hansson, G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vascul. Biol., 2001, 21, 1876-1890.
11. Stefanadi, E.; Tousoulis, D.; Androulakis, E.S.; Papageorgiou, N.; Charakida, M.; Siasos, G.; Tsioufis, C.; Stefanadis, C. Inflammatory markers in essential hypertension: potential clinical implications. Curr. Vascul. Pharmacol., 2010, 8, 509-516.
12. Dessein, P.H.; Joffe, B.I.; Stanwix, A.E. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J. Rheumatol., 2003, 30, 1403-1405.
13. Chen, X.; Xun, K.; Chen, L.; Wang, Y. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem. Func., 2009, 27, 407-416.
14. Kerekes, G.; Soltesz, P.; Der, H.; Veres, K.; Szabó, Z.; Végvári, A.; Shoenfeld, Y.; Szekanecz, Z. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. NY Acad. Sci., 2009, 1173, 814-821.
15. Raterman, H.G.; van Eijk, I.C.; Voskuyl, A.E.; Peters, M.J.; Dijkmans, B.A.; van Halm, V.P.; Simsek, S.; Lems, W.F.; Nurmohamed, M.T. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Ann. Rheum. Dis., 2010, 69, 39-42.
16. Chung, C.P.; Oeser, A.; Solus, J.F.; Avalos, I.; Gebretsadik, T.; Shintani, A.; Raggi, P.; Sokka, T.; Pincus, T.; Stein, C.M. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis, 2008, 196, 756-763.
17. Dessein, P.H.; Norton, G.R.; Woodiwiss, A.J.; Joffe, B.I.; Solomon, A. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J. Rheumatol., 2007, 34, 681-688.
18. Mallbris, L.; Granath, F.; Hamsten, A.; Ståhle, M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol., 2006, 54, 614-621.
19. Herial, N. Prevalence of ischemic heart disease and stroke in multiple sclerosis. CMSC-ACTRIMS, 2012.
20. Dawood T, SM, Brown A, Lambert G., Depression and blood pressure control: All antidepressants are not the same. Hypertension, 2009, 54: e1.
21. Sadovnick, A.D.; Remick, R.A.; Allen, J.; Swartz, E.; Yee I.M.; Eisen, K.; Farquhar, R.; Hashimoto, S.A.; Hooge, J.; Kastrukoff, L.F.; Morrison, W.; Nelson, J.; Oger, J.; Paty, D.W. Depression and multiple sclerosis. Neurol., 1996, 46, 628-632.
22. Kessing, L.V.; Harhoff, M.; Andersen, P.K. Increased rate of treatment with antidepressants in patients with multiple sclerosis. Int. Clin. Psychopharmacol., 2008, 23, 54-59.
23. Licht, C.M.; de Geus, E.J.; Seldenrijk, A.; van Hout, H.P.; Zitman, F.G.; van Dyck, R.; Penninx, B.W. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension, 2009, 53, 631-638.
24. Pistorio, E.; Luca, M.; Luca, A.; Messina, V.; Calandra, C. Autonomic nervous system and lipid metabolism: findings in anxious-depressive spectrum and eating disorders. Lipids Health Dis., 2011, 10, 192.
25. Joyner, M.J.; Charkoudian, N.; Wallin, B.G. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp. Physiol., 2008, 93, 715-724.
26. Cryer, P.E. The barrier of hypoglycemia in diabetes. Diabetes, 2008, 57, 3169-3176.
27. Flachenecker, P.; Reiners, K.; Krauser, M.; Wolf, A.; Toyka, K.V. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult. Scler., 2001, 7, 327-334.
28. Hinojosa-Laborde, C.; Chapa, I.; Lange, D.; Haywood, J.R. Gender differences in sympathetic nervous system regulation. Clin. Exp. Pharmacol. Physiol., 1999, 26, 122-126.
29. Sternberg, Z. Sympathetic nervous system dysfunction in multiple sclerosis, linking neurodegeneration to a reduced response to therapy. Curr. Pharm. Des., 2012, 18, 1635-1644.
30. Corcoran, M.P.; Lamon-Fava, S.; Fielding, R.A. Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise. Am. J. Clin. Nutrit., 2007, 85, 662-677.
31. Adami, S.; Braga, V.; Guidi, G.; Gatti, D.; Gerardi, D.; Fracassi, E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner Res., 2000, 15, 599-604.
32. Vis, M.; Nurmohamed, M.T.; Wolbink, G.; Voskuyl, A.E.; de Koning, M.; van de Stadt, R.; Twisk, J.W.; Dijkmans, B.A.; Lems, W.F. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol., 2005, 32, 252-255.
33. Li, Y.; Wang, C.; Zhu, K.; Feng, R.N.; Sun, C.H. Effects of multivitamin and mineral supplementation on adiposity, energy expenditure and lipid profiles in obese Chinese women. Int. J. Obes. (Lond.), 2010, 34, 1070-1077.
34. Andresdottir, M.B.; Sigfusson, N.; Sigvaldason, H.; Gudnason, V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am. J. Epidemiol., 2003, 158, 844-851.
35. Lonn, E.; Yusuf, S.; Arnold, M.J.; Sheridan, P.; Pogue, J.; Micks, M.; McQueen, M.J.; Probstfield, J.; Fodor, G.; Held, C.; Genest, J. Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. New Engl. J. Med., 2006, 354, 1567-1577.
36. Dhib-Jalbut, S.; Marks, S. Interferon-beta mechanisms of action in multiple sclerosis, Neurology, 2010, 74(Suppl 1), S17-S24.
37. Cheng, T.O. Cardiovascular health, risks and diseases in contemporary China. Int. J. Cardiol., 2012, 154, 233-242.
38. Vacek, J.L.; Vanga, S.R.; Good, M.; Lai, S.M.; Lakkireddy, D.; Howard, P.A. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am. J. Cardiol., 2012, 109, 359-363.
39. Matsunawa, M.; Amano, Y.; Endo, K.; Uno, S.; Sakaki, T.; Yamada, S.; Makishima, M. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicol. Sci. Off. J. Soc. Toxicol., 2009, 109, 50-58.